#ASH20: Gilead's Kite reads out PhII data to back CAR-T player Yescarta in a new indication
In its latest move in a CAR-T battle against Novartis’ Kymriah, Gilead has read out Phase II data to back three-year-old Yescarta in a potential …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
